Related Experiment Video
Updated: Jun 22, 2026
08:37
Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice
Published on: April 21, 2015
Ketotifen effectively prevents mucosal damage in experimental colitis.
1Department of Medicine, Hadassah University Hospital, Jerusalem, Israel.
Gut
|November 1, 1992
Summary
Ketotifen, a mast cell stabilizer, reduced inflammation and mucosal damage in experimental colitis models. This study suggests ketotifen
Area of Science:
- Gastroenterology
- Pharmacology
- Inflammation Research
Background:
- Experimental colitis models are crucial for understanding inflammatory bowel disease (IBD).
- Mast cell activation plays a significant role in the pathogenesis of colitis.
Purpose of the Study:
- To investigate the therapeutic effects of ketotifen, a mast cell stabilizer, on experimental colitis.
- To evaluate ketotifen's impact on inflammatory mediators and mucosal damage in colitis models.
Main Methods:
- Two models of experimental colitis were induced using trinitrobenzene sulphonic acid and acetic acid.
- Ketotifen was administered intragastrically prophylactically and throughout the experimental period.
- Measurements included mucosal damage, inflammatory mediator synthesis (PAF, PGE2, TXB2, LTB4, LTC4), and myeloperoxidase activity.
Main Results:
- Ketotifen significantly decreased mucosal damage in both colitis models.
- A significant reduction in platelet-activating factor, prostaglandin E2, thromboxane B2, and leukotrienes C4 and B4 was observed.
- Myeloperoxidase activity was reduced, particularly in the acetic acid model.
Conclusions:
- Ketotifen demonstrates potential in pharmacologically manipulating experimental colitis.
- Further research is needed to elucidate ketotifen's mechanism of action and its clinical utility in inflammatory bowel disease.
More Related Videos
Related Concept Videos
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:20Inflammatory Bowel Disease II: Ulcerative Colitis
Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...